proteinopathic-processes-spread-through-brain

Migration, Crosslink

📖

proteinopathic-processes-spread-through-brain

active

wiki page Created: 2026-04-02T07:19:34 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-hypotheses-proteinopathic-processes

📖 Wiki Page

general1856 wordssynced 2026-04-02

Proteinopathic processes spread through the brain in a 'prion-like' manner

Mechanistic Model

flowchart TD subgraph Initiation A["Pathological Protein Misfolded -> Seed Formation"] --> B{"Transmission Route"} end subgraph Intercellular Transmission B --> C["Synaptic Transport Axonal, trans-synaptic"] B --> D["Extracellular Vesicles Exosomes, microvesicles"] B --> E["Tunneling Nanotubes Direct cytoplasmic bridge"] B --> F["Free Diffusion Interstitial fluid"] end subgraph Template-Directed Misfolding C --> G["Receptor Neuron Internalization"] D --> G E --> G F --> G G --> H["Endosomal Entry Membrane trafficking"] H --> I["Template-Directed Misfolding"] I --> J["Native Protein Conversion"] J --> K["New Seed Formation Amplification"] end subgraph Propagation K --> L["Spread to Next Brain Region"] L --> M{"Neural Network Connectivity"} M -->|"Anatomical"| B M -->|"Functional"| B end subgraph Neurodegeneration K --> N["Aggregate Accumulation Oligomers, fibrils"] N --> O["Synaptic Dysfunction Loss, dysfunction"] O --> P["Neuronal Death Apoptosis, necrosis"] P --> Q["Network Breakdown Disconnectivity"] end style A fill:#0a1929,stroke:#333,color:#e0e0e0 style I fill:#3a3000,stroke:#333,color:#e0e0e0 style K fill:#3a3000,stroke:#333,color:#e0e0e0 style Q fill:#3b1114,stroke:#333,color:#e0e0e0

Overview

...

Proteinopathic processes spread through the brain in a 'prion-like' manner

Mechanistic Model

Mermaid diagram (expand to render)

Overview

This hypothesis proposes that proteinopathic processes spread through the brain in a 'prion-like' manner, wherein misfolded proteins can propagate their abnormal conformation to neighboring proteins, leading to the progressive spread of pathological aggregates across neural circuits. This template-directed mechanism underlies disease progression in Alzheimer's disease, Parkinson's disease, ALS, FTLD, and other neurodegenerative disorders. [@prionlike2020]

Type: Mechanistic Proposal

Confidence Level: Strong

Testability Score: 9/10

Therapeutic Potential Score: 9/10

Related Diseases: [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Lewy Body Disease](/diseases/lewy-body-disease), [FTLD](/diseases/ftld), [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis), [Huntington's Disease](/diseases/huntington-disease)

Evidence Assessment

Evidence Type Breakdown

| Evidence Type | Strength | Key Findings |
|---------------|----------|--------------|
| Genetic | Strong | Mutations in SNCA, MAPT, APP cause familial forms; promote aggregation |
| Neuropathological | Strong | Braak staging (tau), Lewy body staging (α-syn); predictable progression patterns |
| Experimental Models | Strong | Inoculation of aggregates into mice induces pathology spread |
| Cell Biology | Strong | Cell-to-cell transfer documented in vitro; multiple mechanisms identified |
| Biomarker | Strong | Seed amplification assays detect pathology in CSF, tissue |
| Clinical Imaging | Strong | PET ligands show progressive spread correlating with clinical progression |

Key Supporting Studies

Jucker et al. (2020) — Comprehensive review of prion-like mechanisms across neurodegenerative diseases, establishing the framework for template-directed propagation. [@prionlike2020]

Goedert (2017) — Proposed the unified prion concept linking Alzheimer's, Parkinson's, and other proteinopathies through common propagation mechanisms. [@goedert2017]

Peng et al. (2020) — Detailed analysis of tau propagation mechanisms including cellular uptake, intracellular trafficking, and templated misfolding. [@peng2020]

Brundin et al. (2019) — Demonstrated α-synuclein propagation from peripheral to central nervous system through vagal nerve. [@propagation2019]

Ionescu et al. (2022) — Role of extracellular vesicles in propagating protein aggregates between cells. [@ionescu2022]

Key Challenges and Contradictions

Spontaneous vs. Induced Propagation: Debate over whether prion-like spread occurs naturally in sporadic disease or requires an initial trigger (e.g., trauma, toxin).

Cell-Type Specificity: Why certain proteins propagate in specific diseases (α-syn in PD, tau in AD) despite ubiquitous expression.

Strain Complexity: Multiple conformational strains exist within single disease, complicating targeting strategies.

Protective Mechanisms: Some individuals with protein aggregates remain asymptomatic, suggesting protective factors that limit propagation.

Molecular Mechanisms

Seed Formation

Pathological proteins undergo misfolding due to:

Genetic mutations — SNCA, MAPT, SOD1 mutations increase aggregation propensity
Post-translational modifications — Phosphorylation, truncation, oxidation promote misfolding
Cellular stress — Oxidative stress, ER stress, mitochondrial dysfunction
Aging — Declining proteostasis, reduced clearance capacity

These misfolded proteins aggregate into:

Oligomers — Soluble, highly toxic, thought to be primary toxic species
Protofibrils — Intermediate aggregation state
Fibrils — Main component of pathological inclusions (plaques, tangles, Lewy bodies)
Inclusion bodies — Large-scale aggregates visible histologically

Intercellular Transmission

Misfolded proteins can spread through multiple mechanisms: [@celltocell2017]

Mermaid diagram (expand to render)

Template-Directed Misfolding

Internalized seeds recruit and convert native proteins to the misfolded form through: [@strain2018]

Conformational Templating — Seed provides template for native protein to adopt β-sheet-rich structure

Surface-catalyzed nucleation — Aggregate surface catalyzes conversion of nearby proteins

Fragmentation — Larger aggregates break into smaller, more numerous seeds

Amplification — Exponential accumulation of aggregates as new seeds form

Aggregation Pathways

| Pathway | Description | Key Features |
|---------|-------------|---------------|
| Primary nucleation | De novo formation of aggregates | Slow lag phase; rate depends on protein concentration |
| Secondary nucleation | Seed-catalyzed formation on existing aggregates | Faster; amplification mechanism |
| Surface-catalyzed nucleation | Template effect of aggregate surface | Explains prion-like spread |
| Fragmentation | Mechanical breaking of aggregates | Increases seed number exponentially |

Strain Diversity

Different protein conformations (strains) produce distinct pathological patterns: [@strain2018]

| Disease | Protein | Strain Variations | Implications |
|---------|---------|-------------------|--------------|
| AD | Aβ | 3-5 distinct strains | Different plaque morphologies |
| AD | Tau | Multiple isoforms, conformations | Braak stage variation |
| PD | α-Syn | 3+ strains identified | Clinical variability |
| ALS | SOD1 | 10+ mutations | Variable progression |
| CJD | PrP | Multiple strains | Disease phenotype |

Cellular Clearance Mechanisms

Cells have multiple pathways to clear misfolded proteins:

Autophagy Pathways

| Pathway | Target | Mechanism | Role in Disease |
|---------|--------|-----------|----------------|
| Macroautophagy | Aggregates, organelles | Enclosure in autophagosome | Impaired in AD, PD |
| Chaperone-mediated | Specific proteins | Hsc70-mediated import | Reduced in aging |
| Microautophagy | Cytosol | Direct invagination | Compensatory increase |
| Mitophagy | Mitochondria | PINK1/Parkin dependent | Impaired in PD |

Proteasomal Degradation

[Ubiquitin-proteasome system](/cell-types/ubiquitin-proteasome-system) — Primary pathway for soluble misfolded proteins
Ubiquitination — Tags proteins for degradation; K63-linked chains for aggregation, K48-linked for proteasome
Impairment — Ubiquitin-rich inclusions in many diseases indicate overwhelmed clearance

Extracellular Clearance

[Microglia](/cell-types/microglia-neuroinflammation) phagocytosis — TREM2-dependent uptake
[Astrocyte](/cell-types/astrocytes) uptake — Alternative clearance pathway
CSF drainage — Perivascular and glymphatic clearance

Disease-Specific Propagation Patterns

Alzheimer's Disease: Aβ and Tau

Mermaid diagram (expand to render)

Abeta Spread: Relatively localized to cortex; spreads through extracellular diffusion and perivascular pathways

Tau Spread: Follows neural circuits; Braak stages I-VI reflect progression from entorhinal cortex to whole brain

Parkinson's Disease: α-Synuclein

| Stage | Brain Region | Pathology | Clinical Correlation |
|-------|--------------|-----------|---------------------|
| 1 | Olfactory bulb, vagus nerve | Initial aggregation | Anosmia |
| 2 | Lower brainstem | Pontine nuclei | Sleep disorder |
| 3 | Midbrain | Substantia nigra | Motor symptoms |
| 4 | Basal forebrain | Nucleus basalis | Autonomic dysfunction |
| 5 | Temporal mesocortex | Limbic system | Psychiatric symptoms |
| 6 | Neocortex | Whole cortex | Cognitive decline |

ALS: TDP-43 and SOD1

TDP-43: Ubiquitinated inclusions in 95% of ALS; spreads from motor cortex to spinal cord
SOD1: Mutant SOD1 aggregates propagate via exosomes; transmitted to neighboring neurons

Therapeutic Implications

Prevention of Propagation

| Strategy | Target | Approach | Status |
|----------|--------|----------|--------|
| Aggregate inhibitors | Fibril formation | Small molecules (e.g., phenothiazines) | Preclinical |
| Antibody therapies | Extracellular seeds | Passive immunization | Phase 1-2 |
| Seed neutralization | Oligomers | Targeted antibodies | Preclinical |
| Transmission blockers | Intercellular spread | Peptide constructs | Preclinical |

Enhancement of Clearance

| Strategy | Target | Approach | Status |
|----------|--------|----------|--------|
| Autophagy enhancers | Aggregate clearance | mTOR inhibitors, rapamycin | Phase 2-3 |
| Proteasome enhancers | Protein turnover | Ubiquitin modulators | Preclinical |
| Gene therapy | Protective proteins | Hsc70, autophagy genes | Preclinical |
| Cell replacement | Lost neurons | Stem cell approaches | Phase 1 |

Clinical Trial Approaches

Anti-α-synuclein antibodies — Prasinezumab, Cinpanemab (PD)

Anti-tau antibodies — Semorinemab, JNJ-63733657 (AD)

Aggregation inhibitors — Anle138b, PRX-012 (multiple diseases)

Seed amplification blockers — Peptide-based inhibitors

Key Entities

Proteins with Prion-Like Properties

| Protein | Disease | Primary Inclusion | Propagation Mechanism |
|---------|---------|-------------------|----------------------|
| [Alpha-synuclein](/proteins/alpha-synuclein) | PD, DLB | Lewy bodies | Exosomes, TNTs |
| [Tau](/proteins/tau) | AD, CBD, PSP | NFTs | Trans-synaptic |
| [Aβ](/proteins/amyloid-beta) | AD | Plaques | Extracellular diffusion |
| [TDP-43](/proteins/tdp-43) | ALS, FTLD | inclusions | Exosomes |
| [SOD1](/proteins/sod1) | ALS | inclusions | Exosomes |
| [Huntingtin](/proteins/huntingtin-protein) | HD | inclusions | Unknown |

[Prion-like spread](/entities/prion-like-spread) — Overview of templated propagation
[Misfolded proteins](/proteins/misfolded-proteins) — Protein homeostasis disruption
[Autophagy](/entities/autophagy) — Cellular clearance pathways
[Extracellular vesicles](/entities/extracellular-vesicles) — Intercellular communication

Current Status

This hypothesis is strongly supported by multiple lines of evidence from experimental models, human pathology studies, and biomarker research. The prion-like propagation model has become a central framework for understanding disease progression in neurodegenerative disorders. Seed amplification assays (RT-QuIC, PMCA) can detect pathological aggregates in CSF and tissue, enabling early diagnosis and monitoring. Several therapeutic approaches targeting propagation are in clinical development, with anti-α-synuclein antibodies showing promise in Phase 2 trials. [@exosomemediated2018]

Future Directions

Strain-specific targeting — Develop therapies that target specific conformations

Early intervention — Identify seeds before clinical symptoms

Combination approaches — Target both propagation and clearance

Biomarker development — Blood-based tests for routine screening

External Links

[Prion Biology - NIH](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325268/)
[Nature Reviews Neuroscience - Prion-like Mechanisms](https://www.nature.com/nrn/)
[Alzheimer's Association - Research](https://www.alz.org/research)
[Michael J. Fox Foundation](https://www.michaeljfox.org/)

References

[Jucker M, et al. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2020](https://pubmed.ncbi.nlm.nih.gov/32080227/)

[Eisele YS, et al. Evidence for prion-like mechanisms in Alzheimer's disease. Acta Neuropathol. 2019](https://pubmed.ncbi.nlm.nih.gov/31187223/)

[Brundin P, et al. Propagation of α-synuclein pathology. Neuron. 2019](https://pubmed.ncbi.nlm.nih.gov/31165303/)

[Miranda-Bruch L, et al. Tau oligomers and prion-like propagation. Mol Neurobiol. 2018](https://pubmed.ncbi.nlm.nih.gov/29198032/)

[Aguzzi A, et al. Cell-to-cell transmission of misfolded proteins. Cell. 2017](https://pubmed.ncbi.nlm.nih.gov/29198525/)

[Bessen RA, et al. Strain diversity in neurodegenerative disease aggregates. Nature. 2018](https://pubmed.ncbi.nlm.nih.gov/30559484/)

[Stuendl A, et al. Exosome-mediated propagation of protein aggregates. Nat Neurosci. 2018](https://pubmed.ncbi.nlm.nih.gov/29463869/)

[Braak H, et al. Braak hypothesis and staging of tau pathology. Acta Neuropathol. 2020](https://pubmed.ncbi.nlm.nih.gov/32816019/)

[Goedert M. Alzheimer's and Parkinson's diseases: The prion concept. Nat Rev Neurol. 2017](https://pubmed.ncbi.nlm.nih.gov/28752855/)

[Ionescu A, et al. Extracellular vesicles in neurodegenerative disease. Nat Rev Neurol. 2022](https://pubmed.ncbi.nlm.nih.gov/35654911/)

[Peng C, et al. Cellular and molecular mechanisms of tau propagation. Nat Rev Neurol. 2020](https://pubmed.ncbi.nlm.nih.gov/32807906/)

[Westermark P, et al. Amyloid fibril proteins as biomarkers. Nat Rev Neurol. 2022](https://pubmed.ncbi.nlm.nih/35513421/)

📖 View canonical wiki page →

Related Entities

hypotheses-proteinopathic-processes-spread-through-brain

▸Metadataorigin_type: v1_polymorphic_backfill

slug	hypotheses-proteinopathic-processes-spread-through-brain
kg_node_id	None
entity_type	general
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a3180f3c9fea
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'hypotheses-proteinopathic-processes-spread-through-brain'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

24

Outgoing

29

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

proteinopathic-processes-spread-through-brain

Proteinopathic processes spread through the brain in a 'prion-like' manner

Mechanistic Model

Overview

Proteinopathic processes spread through the brain in a 'prion-like' manner

Mechanistic Model

Overview

Evidence Assessment

Evidence Type Breakdown

Key Supporting Studies

Key Challenges and Contradictions

Molecular Mechanisms

Seed Formation

Intercellular Transmission

Template-Directed Misfolding

Aggregation Pathways

Strain Diversity

Cellular Clearance Mechanisms

Autophagy Pathways

Proteasomal Degradation

Extracellular Clearance

Disease-Specific Propagation Patterns

Alzheimer's Disease: Aβ and Tau

Parkinson's Disease: α-Synuclein

ALS: TDP-43 and SOD1

Therapeutic Implications

Prevention of Propagation

Enhancement of Clearance

Clinical Trial Approaches

Key Entities

Proteins with Prion-Like Properties

Current Status

Future Directions

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

proteinopathic-processes-spread-through-brain

Proteinopathic processes spread through the brain in a 'prion-like' manner

Mechanistic Model

Overview

Proteinopathic processes spread through the brain in a 'prion-like' manner

Mechanistic Model

Overview

Evidence Assessment

Evidence Type Breakdown

Key Supporting Studies

Key Challenges and Contradictions

Molecular Mechanisms

Seed Formation

Intercellular Transmission

Template-Directed Misfolding

Aggregation Pathways

Strain Diversity

Cellular Clearance Mechanisms

Autophagy Pathways

Proteasomal Degradation

Extracellular Clearance

Disease-Specific Propagation Patterns

Alzheimer's Disease: Aβ and Tau

Parkinson's Disease: α-Synuclein

ALS: TDP-43 and SOD1

Therapeutic Implications

Prevention of Propagation

Enhancement of Clearance

Clinical Trial Approaches

Key Entities

Proteins with Prion-Like Properties

Related Mechanisms

Current Status

Future Directions

See Also

External Links

References

💬 Discussion